# Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Source: https://onco.cc/trials/nct05470283/  
OnCo record `nct05470283` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Amsokigene autoleucel run by M.D. Anderson Cancer Center, active and no longer recruiting.

## Summary

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma is a phase 1 interventional study registered as NCT05470283 by M.D. Anderson Cancer Center, with 21 participants planned, started 2022-09-07. Conditions recorded: Tumor, Metastatic Melanoma and Melanoma. Interventions recorded: OBX-115, Acetazolamide, Cyclophosphamide, Furosemide, Mesna and Fludarabine Phosphate.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05470283
- Phase: 1
- Setting: Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 21

## Sources

- ClinicalTrials.gov NCT05470283: https://clinicaltrials.gov/study/NCT05470283

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Amsokigene autoleucel](https://onco.cc/drugs/amsokigene-autoleucel/)
- companies: [Obsidian Therapeutics](https://onco.cc/companies/obsidian-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05470283.json